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PCV4
CLINICAL AND COST OUTCOMES OF VENOUS THROMBOEMBOLISM 
IN PATIENTS WHO UNDERWENT MAJOR ORTHOPEDIC SURGERY
Baser O1, Wang L2, Xie L2
1STATinMED Research/University of Michigan, Ann Arbor, MI, USA; 2STATinMED Research, 
Ann Arbor, MI, USA
OBJECTIVES: To evaluate the effects of venous thromboembolism (VTE) occurring 
within 30 days of hospital discharge after major orthopedic surgery on inpatient costs 
and mortality within 1 year after initial hospitalization for the surgery. METHODS: 
U.S. national Medicare data was used for this analysis. All patients who underwent 
total hip replacement (THR) (n = 51,108) or total knee replacement (TKR) (n = 
115,627) surgery were identiﬁ ed. VTE events were diagnosed within the ﬁ rst 30 days 
and within 1 year post-discharge. Multivariate regression was used to control for 
differences in baseline characteristics in patients with and without VTE events. Total 
cost was measured as Medicare cost plus beneﬁ ciary out-of-pocket cost. RESULTS: 
VTE occurred in 0.74% of patients undergoing THR. For patients with VTE versus 
no VTE, mortality was higher (2.9% vs. 0.4%, P < 0.001). Medicare and total health 
care cost, including the beneﬁ ciary cost share in 1 year, were not different for VTE 
versus no VTE ($19,300 vs. $19,044, p = 0.817), but the beneﬁ ciary cost share was 
higher for VTE ($3,274 vs. $1,966, P < 0.001). VTE occurred in 0.70% of patients 
undergoing TKR. For patients with VTE versus no VTE, mortality was higher (2.5% 
vs. 0.15%, P < 0.001). Total health care cost, including the beneﬁ ciary cost share in 
1 year, was not different for VTE versus no VTE ($17,970 vs. $16,766, p = 0.142), 
but the Medicare and beneﬁ ciary cost shares were both slightly higher for VTE ($3,274 
vs. $1,966 and $2,650 vs. $1,630 for THR and TKR patients, respectively, P < 0.001). 
CONCLUSIONS: VTE after major orthopedic surgery is associated with higher mor-
tality compared with no VTE. VTE did not affect total health care costs in 1 year, 
but beneﬁ ciary costs were higher. Risk-adjusted total, Medicare, and beneﬁ ciary health 
care costs were signiﬁ cantly higher for major orthopedic surgery patients with VTE 
(P < 0.001).
PCV5
COMPARISON OF ADVERSE EVENTS OF MEDICARE PATIENTS WHO 
UNDERWENT KNEE REPLACEMENT SURGERY AND EXPERIENCED 
VENOUS THROMBOEMBOLISM VERSUS NO VENOUS 
THROMBOEMBOLISM
Wang L1, Dysinger A1, Baser O2
1STATinMED Research, Ann Arbor, MI, USA; 2STATinMED Research/University of Michigan, 
Ann Arbor, MI, USA
OBJECTIVES: To estimate re-hospitalization and bleeding rates during the 30 days 
after a venous thromboembolism (VTE) event in patients who underwent knee replace-
ment surgery and to compare the outcomes with patients who did not suffer VTE. 
METHODS: Based on 2004–2006 national Medicare claims, all patients who under-
went knee replacement surgery were identiﬁ ed. The 30 days follow-up event rates for 
patients who had a VTE event during their initial hospitalization were calculated. 
Events were compared between patients who suffered a VTE event and those who did 
not. Risk adjustment was done using propensity score matching (using the ProbChoi-
ceTM algorithm) controlling for baseline demographic and clinical characteristics 
between patients with and without VTE. RESULTS: In patients who underwent total 
knee replacement surgery (n = 104,952), 1.9% had post-operative VTE events during 
their initial hospitalization. Almost 69% (n = 1377) of these patients had deep vein 
thrombosis (DVT), 25% (n = 501) had pulmonary embolism (PE), and 6% (n = 119) 
had both DVT and PE. The overall likelihood of mortality was four times higher for 
VTE patients versus those without VTE (1.35% vs. 0.35%). Patients with VTE during 
their initial hospitalization were more likely to be hospitalized in 30 days compared 
to patients without an event during the same hospital stay (16.62% vs. 8.00%). In 
30 days after the event, patients with VTE were more likely to have bleeding (9.31% 
vs. 2.18%). CONCLUSIONS: VTE events during initial hospitalization for total knee 
replacement surgery patients increased the adverse events compared with no VTE 
events.
PCV6
OUTCOME OF ADVERSE DRUG REACTIONS REGISTERED WITH 
INTENSIVE MONITORING SYSTEM
Mugosa S1, Todorovic Z2, Boskovic A3
1School of Medicine, University of Montenegro, Podgorica, Montenegro; 2School of Medicine, 
University of Belgrade, Belgrade, Serbia; 3Clinical Center of Montenegro, Podgorica, 
Montenegro
OBJECTIVES: Adverse drug reactions (ADR) appear more frequently then what is 
actually reported and registered. The aim was to establish intensive monitoring system 
and to analyze ADR in hospitalized patients. METHODS: Prospective study covered 
200 patients hospitalized in Cardiology Center, Clinical Center of Montenegro. ADR 
were collected in the following way: patients were interviewed on the basis of the 
symptoms list and any signs which could point to eventual ADR. Secondly, lab tests 
and other available parameters were observed. RESULTS: At the time when interviews 
took place, patients received on average 7.96 ± 2.63 medicines (2–17). In total, 67 
patients (34%) had 75 ADR. Twenty-one ADR (28%) are classiﬁ ed as serious. Fifty-
four ADR have resulted in the recovery of the patient (72%), eight had as an outcome 
prolonged hospitalization (11%), another 8 were life threatening (11%), while 5 ADR 
(6%) were the cause of the hospitalization. The most frequent ADR which had as an 
outcome admission to hospital were caused by digoxin (40%), prolonged hospital stay 
by furosemide (38%), while the most frequent registered ADR which were life threat-
ening were caused by streptokinase (50%). CONCLUSIONS: Monitoring ADR in 
patients using cardiovascular drugs is a matter of importance since this class of medi-
cine is usually used by elderly patients with critical conditions and underlying 
diseases.
PCV7
SPONTANEOUS REPORTING OF ADVERSE DRUG REACTIONS 
INVOLVING HOSPITALIZED CARDIAC PATIENTS
Mugosa S1, Todorovic Z2, Boskovic A3
1School of Medicine, University of Montenegro, Podgorica, Montenegro; 2School of Medicine, 
University of Belgrade, Belgrade, Serbia; 3Clinical Center of Montenegro, Podgorica, 
Montenegro
OBJECTIVES: Adverse drug reactions (ADR) in hospital are a signiﬁ cant cause of 
morbidity and mortality. The aim is to analyze the ADR which have been collected 
through doctors’ and medical technicians’ spontaneous reporting. METHODS: The 
prospective study covered 655 patients hospitalized in Cardiology Center of Clinical 
Center of Montenegro. ADR were collected by spontaneous reporting. According to 
the criteria of World Health Organization, for every ADR causality assessment, sever-
ity, type, outcome, level of intervention and place of manifestation of ADR was 
established. RESULTS: In the 6 month period of research at the Cardiology Center, 
655 patients were hospitalized with the average age of 60.72 ± 11.36 years. With 
spontaneous reporting, 22 patients had 22 ADR which were noted. Doctors reported 
a statistically signiﬁ cant larger number of ADR (68%) than medical technicians 
(32%), P < 0,01. Nine patients (41%) had serious ADR with the following outcome: 
21 ADR were the cause of the hospitalization (22%), four ADR resulted in the 
extended hospitalization (44%), and 3 were life threatening (33%). The most frequent 
serious ADR were reported spontaneously by doctors and medical technicians and 
were caused by streptokinase (33%). The most frequent symptoms which the patients 
had as a consequence of ADR were: fainting (27%), headache (18%), weakness 
(14%), vertigo (14%) and vomiting (9%). CONCLUSIONS: Considering increased 
use of cardiovascular drugs and limitations in pre-marketing trials for drug safety 
evaluation, post marketing evaluation of adverse drug reactions induced by this class 
of medicinal products seems necessary.
PCV8
EVALUATION OF CLINICAL AND DIRECT ECONOMIC OUTCOMES 
FOLLOWING AN ACUTE CORONARY EVENT AMONG PATIENTS WITH 
SUBOPTIMAL HDL-C OR TRIGLYCERIDES ADMINISTERED EITHER 
STATIN AND NIACIN EXTENDED-RELEASE OR STATIN 
MONOTHERAPY
Cziraky MJ1, Quinlan S1, Quimbo RA1, Simko RJ2, Webb S2
1HealthCore, Wilmington, DE, USA; 2Abbott Laboratories, Abbott Park, IL, USA
OBJECTIVES: To compare the risk of subsequent coronary event (SCE) and associ-
ated costs between patients maintaining statin monotherapy (SM) or augmenting with 
niacin extended-release (NER) after an acute coronary event (ACE). METHODS: 
Patients with an ACE between January 1, 2004 and March 31, 2009 were identiﬁ ed 
(Index Date was deﬁ ned as the earliest ACE). Patients age ≥18, ≥6 months eligibility 
pre- and post-Index Date, ≥1 statin ﬁ ll and no statin augmenting ﬁ ll 6 months before 
the Index Date, and sub-optimal baseline HDL-C (<40 or <50 mg/dL for men and 
women) or triglyceride (>150 or >200 mg/dL for diabetic and non-diabetic) were 
included. Cohorts were determined based on NER or SM ﬁ lls within 6 months of the 
Index Date (Cohort ID Period). Patients with alternative lipid agents or SCE during 
the Cohort ID Period were excluded. Outcomes included SCE and event-related 
medical costs. SCE risk was compared using Cox proportional hazards models, while 
costs were compared via generalized linear models. Multivariate analyses controlled 
for age, gender, health coverage, geography, co-morbidities, concomitant medications, 
baseline lipids, and severity of initial ACE. RESULTS: A total of 1998 patients added 
NER (n = 145) or maintained SM (n = 1,853) and met all study criteria. NER patients 
were younger (57 ± 8 vs. 61 ± 11, P < 0.0001), less likely female (8% vs. 33%, P = 
0.002), and had lower baseline LDL-C (81 ± 32 vs. 99 ± 41; P < 0.0001), HDL-C (34 
± 7 vs. 40 ± 9; P < 0.0001), and triglycerides (185 ± 118 vs. 208 ± 131; P = 0.0290). 
Compared to SM, NER patients had a 43% lower SCE risk (hazard ratio: 0.57, 
95%CI: 0.35–0.94; P = 0.0274). Clinical ﬁ ndings corresponded with 56% reduction 
in adjusted annual event-related costs compared to SM (0.44; 95% CI: 0.25–0.80 p 
= 0.0068). CONCLUSIONS: Among patients requiring comprehensive lipid manage-
ment, NER demonstrated lower SCE risk compared to SM, consequently reducing 
annual event-related medical costs following an ACE.
PCV9
RATE OF SUBSEQUENT CORONARY EVENTS AND DIRECT ECONOMIC 
OUTCOMES FOLLOWING AN ACUTE CORONARY EVENT BETWEEN 
PATIENTS AUGMENTING STATIN TO FURTHER REDUCE LDL-C VS. 
IMPROVING A COMPREHENSIVE LIPID PROFILE
Quinlan S1, Quimbo RA1, Simko RJ2, Cziraky MJ1, Webb S2
1HealthCore, Wilmington, DE, USA; 2Abbott Laboratories, Abbott Park, IL, USA
OBJECTIVES: Compare the annual subsequent coronary event rate (ASCER) and 
associated costs between patients initiating adjunct therapy with either niacin 
extended-release (NER) for comprehensive lipid panel management or ezetimibe (EZE) 
for continued LDL-C reduction after an acute coronary event (ACE). METHODS: 
Patients with an ACE between January 1, 2004 and May 31, 2009 were identiﬁ ed 
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(Index Date was deﬁ ned as the earliest ACE). Patients age ≥18, ≥6 months eligibility 
pre- and post-Index Date, ≥1 statin ﬁ ll and no statin augmenting ﬁ ll 6 months before 
the Index Date, and sub-optimal baseline HDL-C (<40 or <50 mg/dL for men and 
women) or triglyceride (>150 or >200 mg/dL for diabetic and non-diabetic) were 
included. Cohorts were determined based on NER or EZE ﬁ lls within 6 months of 
the Index Date (Cohort ID Period). Patients with alternative lipid agents or coronary 
event during the Cohort ID Period were excluded. Outcomes included ASCER and 
event-related medical costs and were compared via generalized linear models. Multi-
variate analyses controlled for age, gender, health coverage, geography, co-morbidi-
ties, baseline lipids, and severity of initial ACE. RESULTS: A total of 328 patients 
added NER (n = 145) or EZE (n = 183) and met all study criteria. NER patients were 
less likely female (8% vs. 29%, P < 0.0001), had lower baseline LDL-C (81 ± 32 vs. 
112 ± 40; P < 0.0001) and HDL-C (34 ± 7 vs. 40 ± 9; P < 0.0001). Age (57 ± 8 vs. 
58 ± 10; P = 0.2020), Deyo-Charlson comorbidity index (0.6 ± 1.1 vs. 0.9 ± 1.4; P = 
0.0923) and triglycerides (185 ± 118 vs. 199 ± 94; P = 0.2531) were not statistically 
different. Compared to EZE, NER patients had a 57% decrease in ASCER (incidence 
ratio: 0.43, 95%CI: 0.24–0.77). Clinical ﬁ ndings corresponded with 87% reduction 
in adjusted annual event-related costs compared to EZE (0.13; 95% CI: 0.04–0.41). 
CONCLUSIONS: Among patients requiring lipid management, adopting a compre-
hensive lipid approach demonstrated lower ASCER compared to further reducing 
LDL-C, consequently reducing annual event-related medical costs following an ACE.
PCV10
ANALYSIS OF INAPPROPRIATE SHOCKS IN IMPLANTABLE 
CARDIOVERTER DEFIBRILLATOR (ICD) DEVICES
Neophytou I1, LeReun C2, Diamantopoulos A1
1Symmetron Ltd., London, UK; 2Independent Biostatistician, Carrigaline County, Cork, Ireland
OBJECTIVES: A side effect of implantable cardioverter deﬁ brillator (ICD) devices is 
inappropriate shocks. Shocks are painful, can potentially induce lethal arrhythmias 
and cause severe psychological trauma to cardiac arrhythmic patients. The objective 
of this study was to investigate the risk of inappropriate shocks in patients who receive 
ICD therapy. METHODS: A comprehensive literature search was conducted to iden-
tify studies describing ICD therapy and reporting inappropriate shock data. The 
analysis included studies of patients with implantation performed after 2002, having 
a minimum study population of 50 participants and a minimum 12 month follow up 
period. The database search was augmented by hand searching references of contem-
porary systematic reviews in the area of ICD therapy, to ensure all relevant studies 
were captured. Patient numbers from the identiﬁ ed studies were pooled and summary 
statistics were estimated. RESULTS: A total of 415 published articles were identiﬁ ed 
via the database search. Following abstract and full text review, 32 studies were 
included for data extraction and statistical analysis. a further 4 studies were included 
from the systematic review hand search. The 36 studies provided a combined total of 
807 patients. 16.2% (SD: 11.1) of patients experienced at least one inappropriate 
shock, this was reduced to 15.3% with exclusion of paediatric studies. The median 
duration of follow up was 2.6 years. The average number of inappropriate shocks per 
year for all patients is 0.4 (SD: 0.4). The frequency of inappropriate shocks amongst 
patients who experienced at least one inappropriate shock is 2.2 (SD: 1.7) per year. 
In 11 studies that present detailed information on the nature of shocks 32.9% (SD: 
22.9) of total shock events were recorded as inappropriate. CONCLUSIONS: A high 
proportion of patients in recent trials experienced inappropriate shocks. Future devel-
opment of ICD therapy should focus on the reduction of the inappropriate shock risk.
PCV11
PLATELET FUNCTION TESTS ARE HIGHLY VARIABLE WHEN USED TO 
IDENTIFY PATIENTS RESISTANT TO CLOPIDOGREL
Beard K1, Folia C1, Liovas A2
1Agro Health Associates Inc., Burlington, ON, Canada; 2AstraZeneca Canada Inc., 
Mississauga, ON, Canada
OBJECTIVES: Clopidogrel with aspirin is used to prevent thrombosis. However, 
signiﬁ cant interpatient variability in platelet response to clopidogrel has been reported. 
As many as 33% of patients are considered to be clopidogrel non-responders (NRs). 
a recent meta-analysis has shown that clopidogrel resistance is associated with a 3.5-
fold increased risk of ischemic events. There are several platelet function assays (PFAs) 
available to assess clopidogrel resistance, the gold-standard being light transmission 
aggregometry (LTA). Other PFAs have been developed, including vasodilator-stimu-
lated phosphoprotein phosphorylation (VASP), and VerifyNow® (VN), the latter being 
a point-of-care assay. However PFAs are not frequently used in the clinical setting 
since they are expensive, and time- and labour-intensive. It is of interest to compare 
the reliability of various PFAs in the identiﬁ cation of clopidogrel NRs. METHODS: 
A MEDLINE search was conducted (1966–2010) using the following MeSH terms: 
Clopidogrel, Resistance, and Platelet Function Assay. Patient-based studies which 
compared the proportion of clopidogrel NRs using different PFAs were retrieved. 
RESULTS: Four studies were retrieved. Of these studies, 3 demonstrated signiﬁ cant 
heterogeneity among PFAs in their assessment of clopidogrel responsiveness. The 
proportion of clopidogrel NRs identiﬁ ed with the various PFAs ranged from 13%–
39%, 44%–69%, 35%–90%, and 69%–70% in the 4 studies respectively. CONCLU-
SIONS: The ability to identify clopidogrel NRs by different PFAs varies greatly 
according to the assay used. In addition, LTA and VASP are associated with poor 
quality control, expense and long turnaround times, and they are typically restricted 
to specialized laboratories in research hospitals. The inability of current PFAs to 
accurately assess clopidogrel resistance may place unidentiﬁ ed clopidogrel NRs at 
increased risk of ischemic events. The challenges and costs associated with such tests 
may be eliminated by newer therapies which have less response variability than 
clopidogrel.
PCV12
COMPARATIVE EFFICACY OF EZETIMIBE-STATIN COMBINATION 
THERAPY AND STATIN MONOTHERAPY IN PATIENTS WITH 
HYPERCHOLESTEROLEMIA: SYSTEMATIC REVIEW AND META-
ANALYSIS OF RANDOMISED CONTROLLED TRIALS
Tunceli K1, Lawson RW2, Sibbring GC2, McCormick AL2, Tershakovec AM3, Davies GM3, 
Mikhailidis DP4
1Global Health Outcomes, Merck, Whitehouse Station, NJ, USA; 2Complete Market Access, 
Macclesﬁ eld, Cheshire, UK; 3Merch Research Laboratories, West Point and Upper Gwynedd, 
PA, USA; 4Department of Clinical Biochemistry (Vascular Disease Prevention Clinics), Royal 
Free Hospital Campus, University College London (UCL) Medical School, UCL, London, UK
OBJECTIVES: To review and analyze evidence for the comparative cholesterol-
lowering efﬁ cacy of ezetimibe-statin combination therapy versus statin monotherapy 
in adults with primary hypercholesterolemia. METHODS: MEDLINE, EMBASE, and 
the Cochrane Central Register of Controlled Trials were searched to identify parallel-
group, randomised controlled trials of ezetimibe-statin combination therapy versus 
statin monotherapy, published between January 1993 and March 2010. Studies were 
selected using predeﬁ ned criteria including minimum treatment of 4 weeks. Two review-
ers conducted screening of articles, critical appraisal and data extraction, with a third 
reviewer resolving disagreements. Study quality was assessed using the Cochrane Col-
laboration “risk of bias” assessment tool. The difference between treatments in mean 
percentage change from baseline in low-density lipoprotein cholesterol (LDL-C) and 
proportion of patients attaining LDL-C treatment goal was analyzed. Data were com-
bined by pair-wise, direct comparison random effects meta-analysis, with heterogeneity 
assessed using the I2 statistic. RESULTS: Fifteen articles met selection criteria; 13 
studies involving over 5000 patients could be included in the meta-analyses. Data on 
simvastatin, atorvastatin and rosuvastatin were analyzed. There was a signiﬁ cantly 
greater percentage reduction in LDL-C levels in patients treated with ezetimibe-statin 
monotherapy compared with those treated with statin monotherapy (weighted mean 
difference: 14.11% [95% CI: 16.13, 12.1], P < 0.001), similarly, a greater proportion 
of patients achieved LDL-C goal when treated with ezetimibe-statin combination 
therapy compared with those treated with statin monotherapy (odds ratio 2.38 [95% 
CI: 1.89, 2.94], P < 0.001). The proportion of patients achieving LDL-C goal ranged 
from 12–83% (median 60%) in ezetimibe-statin arms of studies and from 2–52% 
(median 23%) in the statin monotherapy arms. CONCLUSIONS: The results indicate 
that ezetimibe-statin combination therapy is signiﬁ cantly more effective in reducing 
LDL-C levels than increasing the statin monotherapy dose, thereby enabling more 
patients to achieve their LDL-C goal.
PCV13
META REGRESSION ANALYSIS TO INDIRECTLY COMPARE THE SAFETY 
AND EFFICACY OF DALTEPARIN TO ENOXAPARIN FOR THE 
PREVENTION OF VENOUS THROMBOEMBOLIC EVENTS (VTES) IN 
TOTAL HIP REPLACEMENT (THR) SURGERY
Dranitsaris G1, Jelincic V1, Choe Y2
1Augmentium Pharma Consulting, Toronto, ON, Canada; 2Eisai Inc, Woodcliff Lake, NJ, USA
OBJECTIVES: Patients undergoing elective THR surgery are at an increased risk for 
VTEs. Even though dalteparin and enoxaparin have proven clinical effectiveness in 
placebo controlled studies, there have been no head-to-head trials to assess compara-
tive effectiveness. Meta-analytic techniques were used for an indirect statistical com-
parison on the safety and efﬁ cacy between dalteparin and enoxaparin in patients 
undergoing THR surgery. METHODS: A literature search of major databases was 
conducted from 1980 to 2009 for randomized placebo controlled trials evaluating 
both agents in THR patients. Binary outcomes (e.g. VTE rates) for the LMWH group 
relative to control group were statistically pooled using ﬁ xed or random effects models 
in cases of signiﬁ cant heterogeneity. In trials where a common control was used, 
indirect statistical comparisons between dalteparin and enoxaparin were performed 
using meta regression analysis with active drug (dalteparin or enoxaparin) as the 
primary independent variable. RESULTS: A total of nine placebo controlled enoxa-
parin (n = 5) and dalteparin (n = 4) trials met the inclusion criteria. The meta analysis 
of all trial data showed that THR patients treated with enoxaparin or dalteparin had 
a 54% VTE relative risk reduction compared to the placebo (RR = 0.46, p < 0.001). 
This beneﬁ t was achieved without a signiﬁ cant increase in the risk for major bleeds 
(RR = 1.14, p = 0.80), heparin induced thrombocytopenia (HIT) (RR = 0.83, p = 0.75) 
or death (RR = 0.77, p = 0.61). The indirect statistical comparison was not able to 
ﬁ nd signiﬁ cant differences between enoxaparin and dalteparin in terms of VTEs (p = 
0.86), risk of major bleeds (p = 0.46), HIT (p = 0.75) and death (p = 1.0). CONCLU-
SIONS: The ﬁ ndings of the analysis suggest comparable safety and efﬁ cacy between 
dalteparin and enoxaparin in THR patients. Therefore, treatment decisions should be 
based on other considerations such as patient or physician preference, ease of admin-
istration and cost.
